Cisplatin is a platinum containing drug first approved as an antineoplastic agent in 1978. It
remains an important and effective therapy in many forms of cancer today. Cisplatin …

Ovarian cancer is the seventh most common gynaecologic malignancy seen in women.
Majority of the patients with ovarian cancer are diagnosed at the advanced stage making …

Ovarian cancer is the most lethal of all gynecologic malignancies and the eighth leading
cause of cancer-related deaths among women worldwide. The main reasons for this poor …

The transcriptional repressors Snail and Slug contribute to cancer progression by mediating
epithelial-mesenchymal transition (EMT), which results in tumor cell invasion and …

Gynecological cancers are known for being very aggressive at their advanced stages.
Indeed, the survival rate of both ovarian and endometrial cancers is very low when …

Cisplatin (cis-diamminedichloroplatinum (II)) is the oldest known chemotherapeutic agent.
Since the identification of its anti-tumour activity, it earned a remarkable place as a treatment …

OBJECTIVES: Chemotherapy is the preferred therapeutic approach for the therapy of
advanced ovarian cancer, but a successful long-term treatment is prevented by the …

The interplay between p53 and RAS signaling regulates cancer chemoresistance, but the
detailed mechanism is unclear. In this study, we investigated the interactive effects of p53 …

Background Cisplatin resistance is the main cause of poor clinical prognosis in patients with
gastric cancer (GC). Yet, the exact mechanism underlying cisplatin resistance remains …

Mechanical factors in the tumor microenvironment play an important role in response to a
variety of cellular activities in cancer cells. Here, we utilized polyacrylamide hydrogels with …